Aim of the Study
The study aimed to compare the effectiveness and safety of two treatments for non-segmental facial vitiligo: microneedling with tacrolimus 0.03% ointment and microneedling with phenytoin 2% cream.
Materials and Methods
This study involved 40 patients with non-segmental facial vitiligo. They were split into two groups of 20. One group received microneedling with tacrolimus, while the other group received microneedling with phenytoin. Treatments were given every two weeks for six months, followed by a three-month follow-up period.
Results
Both groups had similar demographic and disease characteristics. However, patients treated with microneedling and tacrolimus showed better clinical improvements and higher satisfaction levels compared to those treated with phenytoin. These differences were not statistically significant.
Conclusion
The study suggests that tacrolimus 0.03% ointment combined with microneedling may provide better results than phenytoin 2% cream. Phenytoin also appears to be a viable option for treating non-segmental vitiligo.
Practical Healthcare Results and Solutions
Measurable Outcomes
Clinics should focus on tracking the improvement in skin color and patient satisfaction to evaluate the effectiveness of these treatments.
AI Tools for Clinical Needs
Select AI solutions that can help monitor patient progress and enhance treatment plans based on individual responses to microneedling and topical ointments.
Implementation Steps
Start with a pilot project that uses AI to track treatment outcomes. Assess the real-world impact of both treatment options to inform future practices.
Contact Us for AI Solutions in Medical Management
For more information, reach out via:
- Telegram: https://t.me/itinai
- X: https://x.com/vlruso
- LinkedIn: https://www.linkedin.com/company/itinai/
